Adjuvance Technologies, Inc.
About
Adjuvance Technologies, Inc. is a privately owned biopharmaceutical company dedicated to empowering global health through fundamental breakthroughs in vaccine adjuvant design and manufacturing.
Adjuvance’s founders, including Jeffrey Gardner, David Gin, Philip Livingston and Govindaswami Ragupathi comprise a highly motivated group of experienced individuals eager to commercialize our core technologies in close collaboration with key partnering organizations, such as Memorial Sloan-Kettering Cancer Center.
Our team’s credentials span Medicine, Science and Business. Our world-class experience represents in-depth expertise in chemistry, immunology, adjuvant immunopotentiation and therapeutic vaccinology. Most importantly, our team represents world-leading experience in therapeutic vaccines and vaccine adjuvants, and is experienced in the commercialization of immunotherapeutics.
We believe that our world-class team provides you with more than just a business plan, but a group of impassioned founders and seasoned professionals that are capable of seeing through our mission.
The Team
David Gin
Dr. Gin is a Member and Tri-Institutional Professor in the Molecular Pharmacology and Chemistry Program at the Memorial Sloan-Kettering Cancer Center and Co-founder of Adjuvance. His research program focuses on the chemical synthesis of complex carbohydrate conjugates and bioactive alkaloids.
The synthesis of novel adjuvants for cancer and infectious disease vaccines constitutes a major effort in Dr. Gin’s research. His major innovations in this area form the core of Adjuvance Technologies’ intellectual property.
Dr. Gin obtained his BSc in Chemistry at the University of British Columbia in 1989, received his PhD in synthetic organic chemistry at the California Institute of Technology in 1994, and held a two-year NSERC postdoctoral appointment at Harvard. He began his independent academic career in 1996 at the Chemistry Department at the University of Illinois at Urbana-Champaign, where he remained for 10 years before moving his laboratory to MSKCC in 2006. Dr. Gin’s work has been continuously supported by multiple grants from the National Institutes of Health.
Jeffrey Gardner
Jeffrey R. Gardner is CEO and Co-Founder of Adjuvance Technologies. Prior to the formation of Adjuvance, he has spent close to a decade in the Molecular Pharmacology and Chemistry Program at Memorial Sloan-Kettering Cancer Center. His research focuses on mitochondrial biology in cancer, as well as novel therapeutics, adjuvants and screening methods.
Jeffrey obtained his BSc in Biological Sciences and Chemistry before earning his Masters in Business from NYU in Corporate Finance, Entrepreneurship & Innovation, and Equity Instruments & Markets. Jeffrey’s goal is to build, manage and operate a successful vaccine adjuvant company that engages in novel product development across multiple disciplines and frontier medical markets. Jeffrey is the driving force behind the commercialization of TriSST and he adamantly believes that Adjuvance technology is capable of empowering global health through fundamental breakthroughs in vaccine adjuvant design and manufacturing.
Philip Livingston
Dr. Livingston is a member and Attending Physician, Melanoma and Sarcoma Service, Department of Medicine at Memorial Sloan-Kettering Cancer Center and Co-Founder of Adjuvance. He is the Head of the Laboratory of Tumor Vaccinology at MSKCC where he has treated cancer patients and conducted research for over 30 years. He is a Professor of Medicine at the Weill Graduate School of Medical Sciences of Cornell University.
Dr. Livingston has had extensive preclinical and clinical experience with a variety of adjuvants, and was the first to utilize immunological adjuvant QS-21 in the clinic. He and Dr. Ragupathi have collaborated with Dr Gin in testing the immunogenicity and toxicity of synthetic QS-21 and related adjuvants since Dr Gin’s arrival at MSKCC in 2006.
Dr. Livingston has led the development of cancer vaccines targeting melanomas, sarcomas and cancers of the breast, ovary and prostate, and has extensively published in this subject area. His work continues to be supported by grants from the National Institutes of Health, MSKCC, the US Army, and the Breast Cancer Research Foundation.
Govindaswami Ragupathi
Dr. Ragupathi is an Associate Attending Immunologist in the Melanoma and Sarcoma Service, Department of Medicine, at Memorial Sloan-Kettering Cancer Center and Co-Founder of Adjuvance. He has more than 15 years of experience in developing cancer vaccines against melanoma, prostate cancer, breast cancer, ovarian cancer and small cell-lung cancer. He is a recognized expert in methods for conjugating antigens to carrier molecules, the use of immunological adjuvants to augment antibodies, T-cell levels and effector responses, as well as immunological assays to measure these responses.
As Associate Director of the MSKCC GMP facility, Dr. Ragupathi was also involved in establishing the Class 10,000 Clinical Grade Preparation (CGP) facility for GMP production, formulation and vialing of investigational vaccines and drugs for clinical use.
Dr. Ragupathi obtained his B. Sc in Chemistry at the University of Madras and M. Sc in Biochemistry and Ph.D in Biochemistry at the University of Madras. He has 6 issued US patents and more than 75 publications. Dr Ragupathi has been supported by grants from the US Army, National Institutes of Health, MSKCC, and the Breast Cancer Research Foundation.